evaluation of common genetic disorders in myeloproliferative neoplasms
نویسندگان
چکیده
introduction: the myeloproliferative neoplasms (mpns) are a heterogeneous group of diseases characterized by excessive production of blood cells by hematopoietic precursors. typically, they include polycythemia vera (pv), essential thrombocythemia (et), idiopathic myelofibrosis(imf), and chronic myeloid leukemia (cml). philadelphia chromosome is the final diagnostic test for cml. recently, jak2 mutation introduced as a diagnostic marker for other mpns. the aim of this study is evaluation of philadelphia chromosome in cml patients and jak2 mutation in mpns patients that had been referred to a hematology/oncology clinic in kermanshah between 2010-2011. material and methods: in this study we evaluated common genetic disorders in 124 mpns patients. expression of b2a2 bcr-abl mrna in peripheral blood leucocytes was detected by a reverse transcriptase polymerase chain reaction (rt-pcr) for cml patients. also, we used as-rt-pcr method for the detection of the jak2 mutation for all of 124 patients. results: we found 93.7% cml patients (60/64) with positive philadelphia chromosome. also, 85% pv patients (17/20), 46.6% et patients (14/30) and 40% imf patients (4/10) had jak2 mutation. notably, we found a cml patient with positive philadelphia chromosome and jak2 mutation. conclusion: diagnosis of mpns is often complex and expensive but, jak2 mutation is a sensitive test, relatively cost-effective for proving clonality in mpns. also, more studies are required to determine the exact frequency and prognostic role of the jak2 mutation in philadelphia positive cml patients.
منابع مشابه
Genetic–pathologic characterization of myeloproliferative neoplasms
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by the proliferation of one or more myeloid lineages. The current study demonstrates that three driver mutations were detected in 82.6% of 407 MPNs with a mutation distribution of JAK2 in 275 (67.6%), CALR in 55 (13.5%) and MPL in 6 (1.5%). The mutations were mutually exclusive in principle except in ...
متن کاملEpigenetics in Myeloproliferative Neoplasms
A decade on from the description of JAK2 V617F, the MPNs are circumscribed by an increasingly intricate landscape. There is now evidence that they are likely the result of combined genetic dysregulation, with several mutated genes involved in the regulation of epigenetic mechanisms. Epigenetic changes are not due to a change in the DNA sequence but are reversible modifications that dictate the ...
متن کاملMyeloproliferative Disorders BCR-ABL1—Negative Myeloproliferative Neoplasms: A Review of Molecular Biology, Diagnosis, and Treatment
In 2008, the World Health Organization expanded the classification of myeloproliferative disorders based on increasing amounts of molecular and cytogenetic data. Myeloproliferative neoplasms (MPN) that do not contain the BCR-ABL1 mutation include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). JAK2V617F is the best characterized mutation in BCR-ABL1–nega...
متن کاملThe genetic basis of myeloproliferative disorders.
For many decades, myeloproliferative disorders (MPD) were largely neglected orphan diseases. The conceptual work of William Dameshek in 1951 provided the basis for understanding MPD as a continuum of related syndromes, possibly with a common pathogenetic cause. Recognition of the clonal origin of peripheral blood cells in MPD in 1976 and the ability to grow erythroid colonies in vitro in the ab...
متن کاملGenetic and epigenetic alterations of myeloproliferative disorders.
The classical BCR-ABL negative myeloproliferative neoplasms (MPN) polycythemia vera, essential thrombocythemia, and primary myelofibrosis are clonal hematopoietic disorders characterized by excessive production of terminally differentiated myeloid cells. In MPN patients, the disease can progress to secondary myelofibrosis or acute myeloid leukemia. Clonal hematopoiesis, disease phenotype, and p...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
international journal of hematology-oncology and stem cell researchجلد ۵، شماره ۳، صفحات ۱۶-۲۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023